| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
AACR Annual Meeting 2023
|
Reeves, Cheryl
|
|
|
24 |
5 |
p. e193-e194
|
article
|
| 2 |
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol
|
Attard, Gerhardt
|
|
|
24 |
5 |
p. 443-456
|
article
|
| 3 |
Access to cancer medicines in the UK
|
The Lancet Oncology,
|
|
|
24 |
5 |
p. 415
|
article
|
| 4 |
Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa
|
Petricca, Kadia
|
|
|
24 |
5 |
p. 563-576
|
article
|
| 5 |
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial
|
Mileshkin, Linda R
|
|
|
24 |
5 |
p. 468-482
|
article
|
| 6 |
Alveolar rhabdomyosarcoma with multiple bone marrow infiltration
|
Wang, Kun
|
|
|
24 |
5 |
p. e228
|
article
|
| 7 |
A major conditions strategy cannot replace a national cancer plan—patient advocates voice their concerns
|
Wilson, Roger
|
|
|
24 |
5 |
p. 425-427
|
article
|
| 8 |
ASTRO embraces Final Rule by CMS
|
Das, Manjulika
|
|
|
24 |
5 |
p. e195
|
article
|
| 9 |
Belzutifan: enhancing the blockade of angiogenesis in renal cell carcinoma
|
Mollica, Veronica
|
|
|
24 |
5 |
p. 423-425
|
article
|
| 10 |
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study
|
Choueiri, Toni K
|
|
|
24 |
5 |
p. 553-562
|
article
|
| 11 |
Biden Administration appeals federal judge ruling on ACA
|
Das, Manjulika
|
|
|
24 |
5 |
p. 435
|
article
|
| 12 |
Carcinogenicity of anthracene, 2-bromopropane, butyl methacrylate, and dimethyl hydrogen phosphite
|
Cattley, Russell C
|
|
|
24 |
5 |
p. 431-432
|
article
|
| 13 |
Challenges to patient access to controlled drugs in the USA
|
Devi, Sharmila
|
|
|
24 |
5 |
p. 433
|
article
|
| 14 |
Combination chemo-immunotherapy in advanced oesophageal squamous cell carcinoma
|
Sjoquist, Katrin Marie
|
|
|
24 |
5 |
p. 419-420
|
article
|
| 15 |
Correction to Lancet Oncol 2022; 23: 1308–20
|
|
|
|
24 |
5 |
p. e192
|
article
|
| 16 |
Correction to Lancet Oncol 2023; 24: 403–14
|
|
|
|
24 |
5 |
p. e192
|
article
|
| 17 |
Correction to Lancet Oncol 2022; 23: (Abstracts from The Lancet Summit: Cancer care in Asia and Latin America Special Issue): S28
|
|
|
|
24 |
5 |
p. e192
|
article
|
| 18 |
Craniopharyngiomas and proton beam therapy: worth the expense?
|
Grossman, Ashley
|
|
|
24 |
5 |
p. 422-423
|
article
|
| 19 |
Defining the road map to a UK national lung cancer screening programme
|
O'Dowd, Emma L
|
|
|
24 |
5 |
p. e207-e218
|
article
|
| 20 |
EU cancer drug leaflets contain insufficient information
|
Gourd, Elizabeth
|
|
|
24 |
5 |
p. e196
|
article
|
| 21 |
Evaluating drug delivery enhancement following ultrasound treatment
|
Pouliopoulos, Antonios N
|
|
|
24 |
5 |
p. 420-422
|
article
|
| 22 |
First-in-patient study of OTL78 for intraoperative fluorescence imaging of prostate-specific membrane antigen-positive prostate cancer: a single-arm, phase 2a, feasibility trial
|
Stibbe, Judith A
|
|
|
24 |
5 |
p. 457-467
|
article
|
| 23 |
Fluorescence in prostate cancer surgery
|
Amparore, Daniele
|
|
|
24 |
5 |
p. 417-419
|
article
|
| 24 |
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
|
Hillmen, Peter
|
|
|
24 |
5 |
p. 535-552
|
article
|
| 25 |
Metastatic prostate cancer management: 20 years of progress
|
Gravis, Gwenaelle
|
|
|
24 |
5 |
p. 416-417
|
article
|
| 26 |
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1–2 cm
|
Lamberti, Giuseppe
|
|
|
24 |
5 |
p. e187
|
article
|
| 27 |
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1–2 cm
|
Aktas, Melik Kagan
|
|
|
24 |
5 |
p. e188
|
article
|
| 28 |
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1–2 cm
|
Halfdanarson, Thorvardur R
|
|
|
24 |
5 |
p. e189
|
article
|
| 29 |
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1–2 cm – Authors' reply
|
Kaderli, Reto M
|
|
|
24 |
5 |
p. e190-e191
|
article
|
| 30 |
Proton therapy and limited surgery for paediatric and adolescent patients with craniopharyngioma (RT2CR): a single-arm, phase 2 study
|
Merchant, Thomas E
|
|
|
24 |
5 |
p. 523-534
|
article
|
| 31 |
REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment
|
Ghorani, Ehsan
|
|
|
24 |
5 |
p. e219-e227
|
article
|
| 32 |
Repeated blood–brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial
|
Sonabend, Adam M
|
|
|
24 |
5 |
p. 509-522
|
article
|
| 33 |
Single-arm studies involving patient-reported outcome data in oncology: a literature review on current practice
|
Liu, Limin
|
|
|
24 |
5 |
p. e197-e206
|
article
|
| 34 |
Strategies for cancer-care resilience during the new COVID-19 wave in China
|
Tang, Liang V
|
|
|
24 |
5 |
p. 428-430
|
article
|
| 35 |
Students and researchers from China barred from working in the UK
|
Das, Manjulika
|
|
|
24 |
5 |
p. 434
|
article
|
| 36 |
Sweeping new US EPA air pollution rules
|
Furlow, Bryant
|
|
|
24 |
5 |
p. 438
|
article
|
| 37 |
The European Cancer Pulse: tracking inequalities in cancer control for citizen benefit
|
Couespel, Norbert
|
|
|
24 |
5 |
p. 441-442
|
article
|
| 38 |
The rise of immuno-oncology in China: a challenge to western dominance?
|
Lythgoe, Mark P
|
|
|
24 |
5 |
p. 439-441
|
article
|
| 39 |
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
|
Xu, Jianming
|
|
|
24 |
5 |
p. 483-495
|
article
|
| 40 |
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
|
Strickler, John H
|
|
|
24 |
5 |
p. 496-508
|
article
|
| 41 |
UK Government “swap to stop” plan to cut smoking rates
|
Wilkinson, Emma
|
|
|
24 |
5 |
p. 437
|
article
|
| 42 |
US Government releases National Cancer Plan
|
Furlow, Bryant
|
|
|
24 |
5 |
p. 436
|
article
|
Journal description